Advanced search

Vol 15, No 1 (2022)
Guidelines / Expert consensus
Published online: 2022-03-31

open access

View PDF Download PDF file
Page views 5265
Article views/downloads 714
Get Citation

Connect on Social Media

Connect on Social Media

The Polish Society for Pediatric Nephrology (PTNFD) recommendations on the management of children with nephrotic syndrome

Maria Szczepańska1, Irena Bałasz-Chmielewska2, Ryszard Grenda3, Kinga Musiał4, Iwona Ogarek5, Małgorzata Pańczyk-Tomaszewska6, Jacek Zachwieja7, Aleksandra Żurowska2
DOI: 10.5603/RDTF.2022.0001
Renal Disease and Transplantation Forum 2022;15(1):36-57.

Abstract

On behalf of the Polish Society for Pediatric Nephrology, a group of experts has upgraded the previously announced recommendations* on the management of children with nephrotic syndrome. Recommendations are based on the published European and American guidelines, the results of reliable trials and meta-analyses, as well as local experience. They should be regarded as advisory for pediatricians in their personal experience-driven choice of the optimal available strategy for the diagnostics and treatment of individual pediatric NS patients. The recommendations will be re-updated by the Society in the forthcoming years to account for the continued rapid progress of clinical research and knowledge in the field of glomerulonephritis.  

Keywords: childrenimmunosuppressive therapynephrotic syndromenephrotic syndrome complicationssteroid-resistant nephrotic syndromesteroid-dependent nephrotic syndromesymptomatic therapyvaccinations

Article available in PDF format

View PDF Download PDF file

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis. Kidney Int. ; 2(Suppl. 2012): 139–274.
  2. Rovin BH, Caster DJ, Cattran DC, et al. Conference Participants. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019; 95(2): 281–295.
    CrossRefPubMed
  3. Beck L, Bomback AS, Choi MJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis. 2013; 62(3): 403–441.
    CrossRefPubMed
  4. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis. Kidney Int. 2020; 2: 153–176.
  5. Lombel RM, Gipson DS, Hodson EM, et al. Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol. 2013; 28(3): 415–426.
    CrossRefPubMed
  6. Lombel RM, Gipson DS, Hodson EM, et al. Kidney Disease: Improving Global Outcomes, Kidney Disease: Improving Global Outcomes. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr Nephrol. 2013; 28(3): 409–414.
    CrossRefPubMed
  7. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978; 13(2): 159–165.
    CrossRefPubMed
  8. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003; 362(9384): 629–639.
    CrossRefPubMed
  9. Bierzynska A, Soderquest K, Koziell A. Genes and podocytes - new insights into mechanisms of podocytopathy. Front Endocrinol (Lausanne). 2014; 5: 226.
    CrossRefPubMed
  10. Varner JD, Chryst-Stangl M, Esezobor CI, et al. Genetic testing for steroid-resistant-nephrotic syndrome in an outbred population. Front Pediatr. 2018; 6: 307.
    CrossRefPubMed
  11. Trautmann A, Bodria M, Ozaltin F, et al. PodoNet Consortium. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol. 2015; 10(4): 592–600.
    CrossRefPubMed
  12. Abramowicz M, Barnett HL, Edelmann CM, et al. Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children. The Lancet. 1970; 295(7654): 959–961.
    CrossRef
  13. Feber J, Al-Matrafi J, Farhadi E, et al. Prednisone dosing per body weight or body surface area in children with nephrotic syndrome: is it equivalent? Pediatr Nephrol. 2009; 24(5): 1027–1031.
    CrossRefPubMed
  14. Saadeh SA, Baracco R, Jain A, et al. Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference? Pediatr Nephrol. 2011; 26(12): 2167–2171.
    CrossRefPubMed
  15. Ekka BK, Bagga A, Srivastava RN. Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol. 1997; 11(5): 597–599.
    CrossRefPubMed
  16. Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2007(4): CD001533.
    CrossRefPubMed
  17. Ueda N, Chihara M, Kawaguchi S, et al. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. J Pediatr. 1988; 112(1): 122–126.
    CrossRefPubMed
  18. Ehrich JH, Brodehl J, Brodehl J, et al. The treatment of minimal change nephrotic syndrome (lipoid nephrosis): cooperative studies of the Arbeitsgemeinschaft für Pädiatrische Nephrologie (APN). Klin Padiatr. 1982; 194(3): 162–165.
    CrossRefPubMed
  19. Ksiazek J, Wyszyńska T. Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatr. 1995; 84(8): 889–893.
    CrossRefPubMed
  20. Bagga A, Hari P, Srivastava RN. Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatr Nephrol. 1999; 13(9): 824–827.
    CrossRefPubMed
  21. Hiraoka M, Tsukahara H, Matsubara K, et al. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. American Journal of Kidney Diseases. 2003; 41(6): 1155–1162.
    CrossRef
  22. Lombel RM, Gipson DS, Hodson EM, et al. Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol. 2013; 28(3): 415–426.
    CrossRefPubMed
  23. Ziółkowska H, Bałasz-Chmielewska I, Grenda R, et al. Zalecenia Polskiego Towarzystwa Nefrologii Dziecięcej (PTNFD) dotyczące postępowania z dzieckiem z zespołem nerczycowym. Forum Nefrol. 2015; 8: 238–256.
  24. Teeninga N, Kist-van Holthe JE, van Rijswijk N, et al. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol. 2013; 24(1): 149–159.
    CrossRefPubMed
  25. Sinha A, Saha A, Kumar M, et al. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int. 2015; 87(1): 217–224.
    CrossRefPubMed
  26. Yoshikawa N, Nakanishi K, Sako M, et al. Japanese Study Group of Kidney Disease in Children. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int. 2015; 87(1): 225–232.
    CrossRefPubMed
  27. Hahn D, Hodson EM, Willis NS, et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015(3): CD001533.
    CrossRefPubMed
  28. Hodson EM, Hahn D, Craig JC. Corticosteroids for the initial episode of steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2015; 30(7): 1043–1046.
    CrossRefPubMed
  29. Couderc A, Bérard E, Guigonis V, et al. [Treatments of steroid-dependent nephrotic syndrome in children]. Arch Pediatr. 2017; 24(12): 1312–1320.
    CrossRefPubMed
  30. Pasini A, Benetti E, Conti G, et al. The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse. Ital J Pediatr. 2017; 43(1): 41.
    CrossRefPubMed
  31. Ramachandran R, Jha V. Integration with Kidney Disease Improving Global Outcomes (KDIGO). Glomerulonephritis. 2019: 87–95.
    CrossRef
  32. Webb NJa, Woolley RL, Lambe T, et al. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT. Health Technol Assess. 2019; 23(26): 1–108.
    CrossRefPubMed
  33. Hahn D, Hodson EM, Willis NS, et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015; 30(3): CD001533–1046.
    CrossRefPubMed
  34. Nephrotic syndrome in children: A randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. The Journal of Pediatrics. 1979; 95(2): 228–233.
    CrossRef
  35. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis. Kidney Int. Suppl. 2020; 2: 153–176.
  36. Alternate-day prednisone is more effective than intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr. 1981; 135(3): 229–237.
    CrossRefPubMed
  37. MacDonald NE, Wolfish N, McLaine P, et al. Role of respiratory viruses in exacerbations of primary nephrotic syndrome. J Pediatr. 1986; 108(3): 378–382.
    CrossRefPubMed
  38. Mattoo TK, Mahmoud MA. Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome. Nephron. 2000; 85(4): 343–345.
    CrossRefPubMed
  39. Abeyagunawardena AS, Thalgahagoda RS, Dissanayake PV, et al. Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome. Pediatr Nephrol. 2017; 32(8): 1377–1382.
    CrossRefPubMed
  40. Gulati A, Sinha A, Sreenivas V, et al. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011; 6(1): 63–69.
    CrossRefPubMed
  41. Webb N, Frew E, Brettell E, et al. Short course daily prednisolone therapy during an upper respiratory tract infection in children with relapsing steroid-sensitive nephrotic syndrome (PREDNOS 2): protocol for a randomised controlled trial. Trials. 2014; 15(1).
    CrossRef
  42. Lombel RM, Gipson DS, Hodson EM, et al. Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol. 2013; 28(3): 415–426.
    CrossRefPubMed
  43. Nakanishi K, Iijima K, Ishikura K, et al. Japanese Study Group of Renal Disease in Children. Two-year outcome of the ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome. Clin J Am Soc Nephrol. 2013; 8(5): 756–762.
    CrossRefPubMed
  44. Hodson EM, Knight JF, Willis NS, et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2000(4): CD001533.
    CrossRefPubMed
  45. Gulati A, Sinha A, Sreenivas V, et al. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011; 6(1): 63–69.
    CrossRefPubMed
  46. Webb NJ, Frew E, Brettell EA, et al. for PREDNOS 2 study group. Trials. 2014; 15: 147.
  47. Hahn D, Hodson EM, Willis NS, et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015; 30(3): CD001533–1046.
    CrossRefPubMed
  48. Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev. 2008(1): CD002290.
    CrossRefPubMed
  49. Ishikura K, Ikeda M, Hattori S, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008; 73(10): 1167–1173.
    CrossRefPubMed
  50. Niaudet P. Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol. 1992; 6(1): 1–3.
    CrossRefPubMed
  51. Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant. 1993; 8(12): 1326–1332.
    PubMed
  52. Cammas B, Harambat J, Bertholet-Thomas A, et al. Long-effects of cyclophosphamide therapy in steroid-dependent and frequently relapsing idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2011; 26: 178–184.
  53. Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. 2001; 16(3): 271–282.
    CrossRefPubMed
  54. Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol. 2008; 23(11): 2013–2020.
    CrossRefPubMed
  55. Gellerman J, Querfeld U. Frequently relapsing steroid-sensitive nephrotic syndrome (SSNS) in children and adolescents: treatment with mycophenolate mofetil (MMF) vs cyclosporine (CsA). Pediatr Nephrol. 2011; 26: 1579–1582.
  56. Fujinaga S, Ohtomo Y, Umino D, et al. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol. 2007; 22(1): 71–76.
    CrossRefPubMed
  57. Kirpalani A, Rothfels L, Sharma AP, et al. Nephrotic state substantially enhances apparent mycophenolic acid clearance
. Clin Nephrol. 2019; 91(3): 162–171.
    CrossRefPubMed
  58. Hackl Á, Cseprekál O, Gessner M, et al. Mycophenolate mofetil therapy in children with idiopathic nephrotic syndrome: does therapeutic drug monitoring make a difference? Ther Drug Monit. 2016; 38(2): 274–279.
    CrossRefPubMed
  59. Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008; 23(8): 1269–1279.
    CrossRefPubMed
  60. Ravani P, Rossi R, Bonanni A, et al. Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol. 2015; 26(9): 2259–2266.
    CrossRefPubMed
  61. Sellier-Leclerc AL, Baudouin V, Kwon T, et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery. Nephrol Dial Transplant. 2012; 27(3): 1083–1089.
    CrossRefPubMed
  62. Lombel RM, Gipson DS, Hodson EM, et al. Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol. 2013; 28(3): 415–426.
    CrossRefPubMed
  63. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis. Kidney Int. Suppl. 2020; 2: 153–176.
  64. Chan EYH, Tullus K. Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen. Pediatr Nephrol. 2021; 36(6): 1397–1405.
    CrossRefPubMed
  65. Larkins NG, Liu ID, Willis NS, et al. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev. 2020; 4: CD002290.
    CrossRefPubMed
  66. Sadowski CE, Lovric S, Ashraf S, et al. SRNS Study Group. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2015; 26(6): 1279–1289.
    CrossRefPubMed
  67. Santín S, Bullich G, Tazón-Vega B, et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol. 2011; 6(5): 1139–1148.
    CrossRefPubMed
  68. Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993; 43(6): 1377–1384.
    CrossRefPubMed
  69. Bagga A, Mudigoudar BD, Hari P, et al. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2004; 19(1): 45–50.
    CrossRefPubMed
  70. Trautmann A, Bodria M, Ozaltin F, et al. PodoNet Consortium. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol. 2015; 10(4): 592–600.
    CrossRefPubMed
  71. Shenoy M, Plant ND, Lewis MA, et al. Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome. Pediatr Nephrol. 2010; 25(5): 899–903.
    CrossRefPubMed
  72. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996; 7(1): 56–63.
    CrossRefPubMed
  73. Choudhry S, Bagga A, Hari P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis. 2009; 53(5): 760–769.
    CrossRefPubMed
  74. de Mello VR, Rodrigues MT, Mastrocinque TH, et al. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome. Pediatr Nephrol. 2010; 25(3): 453–460.
    CrossRefPubMed
  75. Gellermann J, Ehrich JHH, Querfeld U. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrol Dial Transplant. 2012; 27(5): 1970–1978.
    CrossRefPubMed
  76. Prytuła A, Iijima K, Kamei K, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010; 25(3): 461–468.
    CrossRefPubMed
  77. Tarshish P, Tobin JN, Bernstein J, et al. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1996; 10(5): 590–593.
    CrossRefPubMed
  78. Elhence R, Gulati S, Kher V, et al. Intravenous pulse cyclophosphamide--a new regime for steroid-resistant minimal change nephrotic syndrome. Pediatr Nephrol. 1994; 8(1): 1–3.
    CrossRefPubMed
  79. Lombel RM, Gipson DS, Hodson EM, et al. Kidney Disease: Improving Global Outcomes, Kidney Disease: Improving Global Outcomes. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr Nephrol. 2013; 28(3): 409–414.
    CrossRefPubMed
  80. Tarshish P, Tobin JN, Bernstein J, et al. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1996; 10(5): 590–593.
    CrossRefPubMed
  81. Jellouli M, Charfi R, Maalej B, et al. Rituximab in the management of pediatric steroid-resistant nephrotic syndrome: A systematic review. J Pediatr. 2018; 197: 191–197.e1.
    CrossRefPubMed
  82. Hackl Á, Cseprekál O, Gessner M, et al. Mycophenolate mofetil therapy in children with idiopathic nephrotic syndrome: Does therapeutic drug monitoring make a difference? Ther Drug Monit. 2016; 38(2): 274–279.
    CrossRefPubMed
  83. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis, Kidney Int. Suppl. ; 2: 153–176.
  84. Trautmann A, Vivarelli M, Samuel S, et al. International Pediatric Nephrology Association. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020; 35(8): 1529–1561.
    CrossRefPubMed
  85. Wyszyńska T, Litwin M, Książek J, Borowski A, Jarmoliński T. Zespół nerczycowy [Nephrotic syndrome]. [In:] Sieniawska M., (Eds). Nefrologia dziecięca, t. I. Ośrodek Informacji Naukowej „Polfa” Sp. z o.o. In: Wyszyńska T, Litwin M, Książek J, Borowski A, Jarmoliński T. ed. Nefrologia dziecięca, t. I. Ośrodek Informacji Naukowej „Polfa” Sp. z o.o., Warszawa 2003.
  86. Grenda R, Pańczyk-Tomaszewska M, Ziółkowska H. Choroby kłębuszków nerkowych [Renal glomerular diseases]. In: Kawalec W, Grenda R, Kulus M. ed. Pediatria, t. I. PZWL, Warszawa 2008.
  87. Cadnapaphornchai MA, Tkachenko O, Shchekochikhin D, et al. The nephrotic syndrome: pathogenesis and treatment of edema formation and secondary complications. Pediatr Nephrol. 2014; 29(7): 1159–1167.
    CrossRefPubMed
  88. Bockenhauer D. Over- or underfill: not all nephrotic states are created equal. Pediatr Nephrol. 2013; 28(8): 1153–1156.
    CrossRefPubMed
  89. Ellis D. Pathophysiology, evaluation, and management of edema in childhood nephrotic syndrome. Front Pediatr. 2015; 3: 111.
    CrossRefPubMed
  90. Kallash M, Mahan JD. Mechanisms and management of edema in pediatric nephrotic syndrome. Pediatr Nephrol. 2021; 36(7): 1719–1730.
    CrossRefPubMed
  91. Kitsios GD, Mascari P, Ettunsi R, et al. Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis. J Crit Care. 2014; 29(2): 253–259.
    CrossRefPubMed
  92. Pasini A, Benetti E, Conti G, et al. The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse. Ital J Pediatr. 2017; 43(1): 41.
    CrossRefPubMed
  93. Keenswijk W, Ilias MI, Raes A, et al. Urinary potassium to urinary potassium plus sodium ratio can accurately identify hypovolemia in nephrotic syndrome: a provisional study. Eur J Pediatr. 2018; 177(1): 79–84.
    CrossRefPubMed
  94. Kerlin BA, Blatt NB, Fuh B, et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr. 2009; 155(1): 105–10, 110.e1.
    CrossRefPubMed
  95. Bauman M, Massicotte MP, Yiu V. Disordered hemostasis and renal disorders. In: Geary DF, Schaefe F. ed. Comprehensive pediatric nephrology. Mosby 2008: 385–394.
  96. KDIGO General principles in the management of glomerular disease. Kidney Int. Suppl. 2012; 2: 156–162.
  97. Zaffanello M, Franchini M. Thromboembolism in childhood nephrotic syndrome: a rare but serious complication. Hematology. 2007; 12(1): 69–73.
    CrossRefPubMed
  98. Ziółkowska H. Zespół nerczycowy. Pediatr Dypl. 2013; 17: 17–28.
  99. Lilova MI, Velkovski IG, Topalov IB. Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1974-1996). Pediatr Nephrol. 2000; 15(1-2): 74–78.
    CrossRefPubMed
  100. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol. 2007; 18(8): 2221–2225.
    CrossRefPubMed
  101. Grenda R, Ziółkowska H. Choroby układu moczowego. In: Kawalec W, Grenda R, Ziółkowska H. ed. Pediatria. PZWL, Warszawa 2013: 657–740.
  102. Park SeJ, Shin JIl. Complications of nephrotic syndrome. Korean J Pediatr. 2011; 54(8): 322–328.
    CrossRefPubMed
  103. Yang GF, Schoepf UJ, Zhu H, et al. Thromboembolic complications in nephrotic syndrome: imaging spectrum. Acta Radiol. 2012; 53(10): 1186–1194.
    CrossRefPubMed
  104. Kerlin BA, Haworth K, Smoyer WE. Venous thromboembolism in pediatric nephrotic syndrome. Pediatr Nephrol. 2014; 29(6): 989–997.
    CrossRefPubMed
  105. Suri D, Ahluwalia J, Saxena AK, et al. Thromboembolic complications in childhood nephrotic syndrome: a clinical profile. Clin Exp Nephrol. 2014; 18(5): 803–813.
    CrossRefPubMed
  106. Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e737S–e801S.
    CrossRefPubMed
  107. Wright JM, Watts RG. Venous thromboembolism in pediatric patients: epidemiologic data from a pediatric tertiary care center in Alabama. J Pediatr Hematol Oncol. 2011; 33(4): 261–264.
    CrossRefPubMed
  108. Pasini A, Benetti E, Conti G, et al. The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse. Ital J Pediatr. 2017; 43(1): 41.
    CrossRefPubMed
  109. Carpenter SL, Goldman J, Sherman AK, et al. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr Nephrol. 2019; 34(2): 261–267.
    CrossRefPubMed
  110. Prescott WA, Streetman DaD, Streetman DS. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother. 2004; 38(12): 2105–2114.
    CrossRefPubMed
  111. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003; 362(9384): 629–639.
    CrossRefPubMed
  112. Saland JM, Ginsberg H, Fisher EA. Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr. 2002; 14(2): 197–204.
    CrossRefPubMed
  113. Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. Pediatrics. 2009; 124(2): 747–757.
    CrossRefPubMed
  114. Avis HJ, Hutten BA, Gagné C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010; 55(11): 1121–1126.
    CrossRefPubMed
  115. de Jongh S, Ose L, Szamosi T, et al. Simvastatin in Children Study Group. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002; 106(17): 2231–2237.
    CrossRefPubMed
  116. Knipscheer HC, Boelen CC, Kastelein JJ, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res. 1996; 39(5): 867–871.
    CrossRefPubMed
  117. McCrindle BW, Helden E, Cullen-Dean G, et al. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res. 2002; 51(6): 715–721.
    CrossRefPubMed
  118. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003; 143(1): 74–80.
    CrossRefPubMed
  119. Stein EA, Illingworth DR, Kwiterovich PO, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999; 281(2): 137–144.
    CrossRefPubMed
  120. Chapter 4: Pharmacological cholesterol-lowering treatment in children. Kidney Int Suppl (2011). 2013; 3(3): 282–283.
    CrossRefPubMed
  121. Dogra GK, Watts GF, Herrmann S, et al. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int. 2002; 62(2): 550–557.
    CrossRefPubMed
  122. Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations, and future directions. Pediatrics. 2007; 119(2): 370–380.
    CrossRefPubMed
  123. Noone D, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. The Lancet. 2018; 392(10141): 61–74.
    CrossRef
  124. Banerjee S, Basu S, Sengupta J. Vitamin D in nephrotic syndrome remission: a case-control study. Pediatr Nephrol. 2013; 28(10): 1983–1989.
    CrossRefPubMed
  125. Weng FL, Shults J, Herskovitz RM, et al. Vitamin D insufficiency in steroid-sensitive nephrotic syndrome in remission. Pediatr Nephrol. 2005; 20(1): 56–63.
    CrossRefPubMed
  126. Mittal SK, Dash SC, Tiwari SC, et al. Bone histology in patients with nephrotic syndrome and normal renal function. Kidney Int. 1999; 55(5): 1912–1919.
    CrossRefPubMed
  127. Freundlich M, Jofe M, Goodman WG, et al. Bone histology in steroid-treated children with non-azotemic nephrotic syndrome. Pediatr Nephrol. 2004; 19(4): 400–407.
    CrossRefPubMed
  128. Gulati S, Godbole M, Singh U, et al. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease? American Journal of Kidney Diseases. 2003; 41(6): 1163–1169.
    CrossRef
  129. Choudhary S, Agarwal I, Seshadri MS. Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study. Pediatr Nephrol. 2014; 29(6): 1025–1032.
    CrossRefPubMed
  130. Banerjee S, Basu S, Sen A, et al. The effect of vitamin D and calcium supplementation in pediatric steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2017; 32(11): 2063–2070.
    CrossRefPubMed
  131. Yadav VK, Sharma S, Debata PK, et al. Change in bone mineral density and role of vitamin D and calcium supplementation during treatment of first episode nephrotic syndrome. J Clin Diagn Res. 2017; 11(9): SC18–SC21.
    CrossRefPubMed
  132. Selewski DT, Chen A, Shatat IF, et al. Vitamin D in incident nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol. 2016; 31(3): 465–472.
    CrossRefPubMed
  133. Emma F, Sesto A, Rizzoni G. Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol. 2003; 18(8): 783–788.
    CrossRefPubMed
  134. Donatti TL, Koch VH, Fujimura MD, et al. Growth in steroid-responsive nephrotic syndrome: a study of 85 pediatric patients. Pediatr Nephrol. 2003; 18(8): 789–795.
    CrossRefPubMed
  135. Elzouki AY, Jaiswal OP. Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood. Effect on remission, statural growth, obesity, and infection rate. Clin Pediatr (Phila). 1988; 27(8): 387–392.
    CrossRefPubMed
  136. Jabs K, Sullivan EK, Avner ED, et al. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation. 1996; 61(1): 31–36.
    CrossRefPubMed
  137. Chapter 3: Steroid-sensitive nephrotic syndrome in children. Kidney Int Suppl (2011). 2012; 2(2): 163–171.
    CrossRefPubMed
  138. Czajka H, Wysocki J. Szczepienia w profilaktyce chorób zakaźnych. Vademecum. Helpmed, Kraków 2010.
  139. Rubik J. Szczepienia u pacjentów nefrologicznych — kiedy i jakie szczepionki są konieczne? Klinika Pediatryczna. 2008; 16: 350–353.
  140. Komunikat Głównego Inspektora Sanitarnego z dnia 31 października 2017 r. w sprawie Programu Szczepień Ochronnych na rok 2018. Dziennik Urzędowy Ministra Zdrowia, poz. 108 z 31 października 2017 r.
  141. Immunisation guideline for children with chronic kidney disease. Renal Unit Royal Hospital for Sick Children Yorkhill Division, Nov. 2011;. https://www.clinicalguidelines.scot.nhs.uk/nhsggc-paediatric-clinical-guidelines/nhsggc-guidelines/kidney-diseases/immunisation-guideline-for-children-with-chronic-kidney-disease/.
  142. Nuorti JP, Whitney CG. Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010; 59(RR-11): 1–18.
    PubMed
  143. https://publications.aap.org/redbook.
  144. http://www.cdc.gov/vaccines/schedules/hcp/index.html.
  145. Alpay H, Yildiz N, Onar A, et al. Varicella vaccination in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2002; 17(3): 181–183.
    CrossRefPubMed
  146. Poyrazoğlu HM, Düşünsel R, Gündüz Z, et al. Antibody response to influenza A vaccination in children with nephrotic syndrome. Pediatr Nephrol. 2004; 19(1): 57–60.
    CrossRefPubMed
  147. Ulinski T, Leroy S, Dubrel M, et al. High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone. Pediatr Nephrol. 2008; 23(7): 1107–1113.
    CrossRefPubMed
  148. Immunisation of the immunocompromised child. Best Practice Statement. February 2002. Royal College of Paediatrics and Child Healt. http://rcpch.adlibhosting.com/files/Immunisation%20of%20the%20Immunocompromised%20Child%C2%A02002-02.pdf..
  149. Janus N, Vacher LV, Karie S, et al. Vaccination and chronic kidney disease. Nephrol Dial Transplant. 2008; 23(3): 800–807.
    CrossRefPubMed
  150. Kamei K, Miyairi I, Ishikura K, et al. Prospective study of live attenuated vaccines for patients with nephrotic syndrome receiving immunosuppressive agents. J Pediatr. 2018; 196: 217–222.e1.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Renal Disease and Transplantation Forum

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice